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Impact of a Multidisciplinary Thoracic Oncology Clinic on
the Timeliness of Care
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Gustavo S. Montana, MD,§ Gilbert Schreiber, MD, PhD, and Michael J. Kelley, MD*
Background: Multidisciplinary clinics have been recommended for
the evaluation of patients with lung cancer. Evidence to support this
recommendation, however, is limited. A single-center, retrospective
review of lung cancer patients at a Veterans Affairs hospital was
performed comparing timeliness of diagnostic and treatment deci-
sions during the operation of a multidisciplinary thoracic oncology
clinic (MTOC) with a period after it closed (non-MTOC), during
which only a weekly multidisciplinary conference was held.
Methods: Patients were identified from a tumor registry. Manual
chart reviews were performed on all patients. Outcome measures
included time from initial presentation to diagnosis (TTD) and time
from diagnosis to treatment initiation (TTT).
Results: Three hundred forty-five patients (244 in MTOC, 101 in
non-MTOC) diagnosed with lung cancer between 1999 and 2003
were included in the study. Baseline characteristics were similar
between the two groups. Median TTD was 48 days (95% confidence
interval [CI]: 37–61) and 47 days (95% CI: 39–55) in the MTOC
(n 164) and non-MTOC cohorts (n 89), respectively (p 0.09).
Median TTT was 22 days (95% CI: 20–27) and 23 days (95% CI:
20–34) in the MTOC (n  165) and non-MTOC cohorts (n  89),
respectively (p  0.71). There was no difference in overall survival.
Conclusion: Retrospective comparison of sequential cohorts failed
to reveal benefit in the timeliness of care measures during the time
period of MTOC operation. Potential confounders include the ab-
sence of a surgeon in the MTOC setting, an ongoing weekly
multidisciplinary conference in the non-MTOC cohort, and existing
infrastructures based on previous MTOC experiences and past
provider experience. Confirmation of these findings in other health
care settings is warranted, preferably in a prospective fashion.
Key Words: Lung cancer, Integrated health team, Multidisciplinary
clinic.
(J Thorac Oncol. 2006;1: 692–696)
Lung cancer is the most common cause of cancer death inthe United States, with an estimated 175,000 newly diag-
nosed cases this year.1 Median survival for all lung cancer
patients in the Surveillance Epidemiology and End Results
tumor registry is approximately 9 months and varies by stage
and histology.2 Non-small cell lung cancer (NSCLC) ac-
counts for 85% of lung cancer, with small cell lung cancer
accounting for 12% to 15% of cases. The evaluation and
treatment of individuals with lung cancer often involve mul-
tiple medical specialists including pulmonologists, radiolo-
gists, pathologists, thoracic surgeons, and radiation and med-
ical oncologists. Multidisciplinary clinics are advocated to
coordinate the patient’s care among these various disciplines
expeditiously. There is a limited amount of published data in
lung cancer on the efficacy of multidisciplinary oncology
clinics.
The American College of Chest Physicians recently
published evidence-based patient management guidelines for
the care of lung cancer patients.3 A multidisciplinary ap-
proach, with initial evaluation in a multidisciplinary lung
cancer clinic, was recommended for individuals with lung
cancer and was thought to be especially beneficial for those
requiring multimodality therapies. Evidence to support this
recommendation was based largely on expert opinion.
The British Thoracic Society published guidelines in
1998 advocating for expedited evaluation, diagnosis, and
treatment of individuals with lung cancer.4 The recommen-
dations are for all patients to be seen within 1 week of
referral, diagnostic tests be performed within 2 weeks, sur-
gery within 4 to 8 weeks, chemotherapy initiated within 7
working days of a diagnosis, and radiation therapy initiated
within 2 days (urgent), 4 weeks (radical), and 2 weeks
(palliative). In addition, it was recommended that a multidis-
ciplinary lung cancer conference meet regularly and a mul-
tidisciplinary lung cancer clinic be established. Evidence to
support these recommendations, however, was graded as
“poor” and reflected a lack of quality studies.
To evaluate the impact of a multidisciplinary clinic, we
retrospectively compared outcome measures at a single insti-
tution in sequential cohorts of lung cancer patients evaluated
during the operation of a multidisciplinary thoracic oncology
clinic (MTOC) and a subsequent period when the MTOC did
not exist. Time to diagnosis (TTD) and time to treatment
(TTT) were selected as primary outcome measures, reasoning
that these would be most directly affected by the presence of
a multidisciplinary clinic.
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METHODS
Patients diagnosed with lung cancer at the Durham
Veterans Medical Center (DVAMC) between the years of
1999 and 2003 were eligible for inclusion. Two sequential
cohorts were identified; one cohort during the years of MTOC
operation (MTOC cohort) and a second during the years
when MTOC was nonoperational (non-MTOC) (Fig. 1). The
MTOC closed June 2002 due to a key MTOC provider
leaving the institution. The MTOC included pulmonology,
medical oncology, and radiation oncology. The pulmonolo-
gist organized the clinic, but multidisciplinary discussions
occurred before and during a patient’s visit between special-
ists from medical oncology, radiation oncology, and pulmo-
nary medicine. Patients were seen by specific providers based
on expected clinical stage and first treatment. Patients would
be seen sequentially on the same visit by subspecialists as
needed based on the initial evaluation. A multidisciplinary
weekly case conference was held during the period of oper-
ation of the MTOC clinic and continued subsequently after
the MTOC ceased operations. The conference was attended
by representatives of the above specialties as well as mem-
bers of pathology, radiology, and thoracic surgery. Patients
without a confirmed diagnosis, nonlung malignancy, diagno-
sis at an outside facility, or primary evaluation and treatment
as an inpatient were excluded. Patients who were diagnosed
or treated as outpatients, after an initial inpatient evaluation,
were eligible and included. A tumor registry, maintained at
the DVAMC, was used to identify potentially eligible pa-
tients. Manual chart reviews were performed to confirm
eligibility and inclusion criteria. The study was approved by
the DVAMC Institutional Review Board, which granted a
waiver of consent.
This study was designed to assess the timeliness of care
at a single institution during the time periods in which the
MTOC did and did not exist. Primary outcomes (Fig. 2) of
interest included TTD and TTT. TTD was defined as the
number of days from the first visit to any physician for a
cancer-related sign/symptom or radiographic evidence to the
date of pathologic diagnosis. To assess the impact of the
MTOC on the TTD for this institution, only patients in whom
a diagnosis had been made at DVAMC were included. TTT
was defined as the number of days from diagnosis to the date
of treatment initiation. Treatment refers to individuals who
received surgery, chemotherapy, or radiation therapy. Sup-
portive measures and palliative care were not considered
active treatments for the purposes of this study.
Secondary outcomes (Fig. 2) included the following:
(a) referral time, the number of days from first visit to any
physician for a cancer-related sign/symptom or radiographic
evidence, in asymptomatic patients, to the date first seen in
the MTOC or corresponding subspecialty clinic during the
years that the MTOC was nonoperational;(b) subspecialty
clinic to diagnosis (SCTD), the number of days from date first
seen in the MTOC or corresponding subspecialty clinic dur-
ing the years that the MTOC was nonoperational to the date
of diagnosis; (c) subspecialty clinic to surgery (SCTS), num-
ber of days from the date first seen in the MTOC or corre-
sponding subspecialty clinic during the years that the MTOC
was nonoperational to the date of surgery as a treatment
modality; (d) overall survival, the number of days from the
date of pathologic diagnosis to death from all causes, with
patients alive as of January 1, 2005, censored. Patients for
whom the date of first physician visit/radiographic evidence
of a cancer-related sign/symptom, date first seen in the
MTOC, date of diagnosis and/or date of treatment initiation
could not be confirmed were excluded from particular out-
comes of interest.
Assuming 165 patients in MTOC and 90 in non-MTOC
with valid measure of the endpoints, this study has approxi-
mately an 85% power to detect a 34% decrease in the median
TTD from 50 days for non-MTOC to 33 days for MTOC. In
addition, it has approximately an 85% power to detect a 32%
decrease in median TTT from 25 days for non-MTOC to 17
days for MTOC. These calculations are based on a two-sided
significance level of 5%.
Chi-square tests were used to compare baseline char-
acteristics for categorical variables between cohorts; p values
from Fisher’s exact test were used whenever appropriate. A
nonparametric Wilcoxon test was used to compare baseline
characteristics for continuous variables, such as age, between
cohorts. The log-rank test was used to compare the primary
endpoints, TTD and TTT, secondary endpoints, and overall
survival between cohorts. A Kaplan-Meier curve was gener-
ated for overall survival by cohort.
FIGURE 1. Study timeline and associated analyses. MTOC,
operational multidisciplinary thoracic oncology clinic; Non-
MTOC, nonoperational multidisciplinary thoracic oncology
clinic.
FIGURE 2. Schema of primary and secondary outcomes.
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RESULTS
Five hundred eight potentially eligible patients were
identified from the tumor registry (Fig. 3). One hundred
sixty-three patients were excluded for the following reasons:
126 were evaluated and treated as inpatients only, 23 were
diagnosed at an outside facility, and 14 had no confirmed
pathologic diagnosis. Three hundred forty-five patients were
eligible and analyzed for the primary outcomes of interest:
244 in the MTOC cohort and 101 in the non-MTOC cohort.
Clinical characteristics for the two cohorts are identi-
fied in Table 1. All subjects were male with a median age of
68 years and 65 years in the MTOC and non-MTOC cohorts,
respectively (p  0.04). There were no significant proportion
differences between cohorts with respect to age (younger than
65 or 65 years and older), race, histological diagnoses, clin-
ical stage, or smoking history for primary or secondary
outcomes (p  0.05).
To determine whether the presence of MTOC had an
overall effect on the timeliness of diagnosis and treatment in
lung cancer patients, an analysis was performed in which
MTOC was evaluated as an intervention over time (intention
to treat [ITT]; Table 2). All patients during the period of
MTOC operation were included in the MTOC cohort regard-
less of whether they were seen in the MTOC clinic. Median
TTD was 45 days (95% confidence interval [CI]: 37–58) and
47 days (95% CI: 39–55) in the MTOC (n  201) and
non-MTOC (n  89) cohorts, respectively (p  0.12). Me-
dian TTT was 21 days (95% CI: 18–25) and 23 days (95%
CI: 20–34) in the MTOC (n 205) and non-MTOC (n 89)
cohorts, respectively (p  0.38).
To determine whether the multidisciplinary clinic may
have benefited the subgroup of patients seen in the clinic, the
analysis was repeated considering the MTOC as an interven-
tion received and including only those individuals actually
evaluated in the MTOC clinic (treatment received [Table 2]).
The median TTD was 48 days (95% CI: 37–61) and 47 days
(95% CI: 39–55) in the MTOC (n  164) and non-MTOC
(n  89) cohorts, respectively (p  0.09). Median TTT was
22 days (95% CI: 20–27) and 23 days (95% CI: 20–34) in the
MTOC (n  165) and non-MTOC (n  89) cohorts, respec-
tively (p  0.71).
About two thirds of patients in each cohort had been
referred from outside facilities. To consider the possibility of
lack of timeliness in these referrals, we explored referral time
bias as a potential confounder that might have masked any
benefit provided by the MTOC. The median referral time was
25 days (95% CI: 22–29) and 22 days (95% CI: 18–26) in the
MTOC (n  164) and non-MTOC (n  90) cohorts, respec-
tively (p  0.01). We examined whether this statistically
FIGURE 3. Patient selection schema. MTOC, operational
multidisciplinary thoracic oncology clinic; Non-MTOC, non-
operational multidisciplinary thoracic oncology clinic.
TABLE 1. Clinical Characteristics of Sequential Cohorts of
Lung Cancer Patients
Patient characteristics
MTOC
(n  244)
Non-MTOC
(n  101) p value
Median age, y (range) 68 (44–88) 65 (40–85) 0.04
Age
65 84 (34%) 42 (42%) 0.20
65 160 (66%) 59 (58%)
Sex (M:F) 244:0 101:0 n/a
Race
White 169 (69%) 72 (71%) 0.91a
African American 73 (30%) 28 (28%)
Native American 1 (0.5%) 0 (0%)
Other 1 (0.5%) 1 (1%)
Histology
NSCLC 197 (81%) 82 (81%) 0.11
SCLC 25 (10%) 13 (13%)
Other 22 (9%) 6 (6%)
Stage (NSCLC/other)
Local
I/II 92 (42%) 32 (36%) 0.24
Regional
IIIa/IIIb 54 (25%) 21 (24%)
Advanced
IV 63 (28%) 25 (28%)
Other
Unknown 11 (5%) 10 (12%)
Stage (SCLC)
Limited 8 (32%) 8 (62%) 0.08
Extensive 17 (68%) 5 (38%)
Smokers 244 (100%) 101 (100%) n/a
p Value is calculated from the Wilcoxon test.
a Native American and other are combined.
MTOC, operational multidisciplinary thoracic oncology clinic; Non-MTOC, non-
operational multidisciplinary thoracic oncology clinic; n/a, not available; NSCLC,
non-small cell lung cancer; SCLC, small cell lung cancer.
TABLE 2. Comparison Between Cohorts for Primary and
Secondary Outcomes
Outcomes MTOC Non-MTOC p value
Time to diagnosis
ITT 45 (n  201) 47 (n  89) 0.12
TR 48 (n  164) 0.09
Time to treatment
ITT 21 (n  205) 23 (n  89) 0.38
TR 22 (n  165) 0.71
Referral time 25 (n  162) 22 (n  90) 0.01
Subspecialty clinic to diagnosis 12 (n  166) 14 (n  90) 0.97
Subspecialty clinic to surgery 50 (n  56) 40 (n  30) 0.21
Analyses performed as intention to treat (ITT) and treatment received (TR) for
primary outcomes. Secondary outcome analysis performed as treatment received.
Outcomes presented in median days.
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significant longer referral time in the MTOC groups was
clinically significant by comparing the median time from first
subspecialty clinic date to date of diagnosis (SCTD). The
median SCTD was 12 days (95% CI: 8–14) and 14 days
(95% CI: 10–25) in the MTOC (n  166) and non-MTOC
cohorts (n  87), respectively (p  0.97).
The time from subspecialty clinic to surgery (SCTS), as
a treatment modality, was analyzed to determine whether the
presence of the MTOC shortened or delayed time to surgery
for individuals with early-stage lung cancer. Although sur-
geons participated in the weekly multidisciplinary confer-
ence, they did not attend the formal clinic itself. The median
SCTS was 50 days (95% CI: 44–63) and 40 days (95% CI:
35–49) in the MTOC (n  56) and non-MTOC cohorts (n 
30), respectively (p  0.21).
Overall survival proportion in each cohort, for patients
with NSCLC, is shown in Figure 4. Median survival was 1.0
year (95% CI: 0.81–1.33) and 1.2 years (95% CI: 0.91–2.12)
for the MTOC, as intention to treat, and non-MTOC cohorts,
respectively (p  0.39). Median survival was 1.3 years (95%
CI: 0.92–1.71) for MTOC as a treatment received (p  0.99
compared to non-MTOC). Follow-up time for the non-
MTOC cohort is short.
Analysis of clinical trial enrollment between cohorts
revealed a significant difference. A total of 55 MTOC pa-
tients, during the period of study, enrolled in a clinical trial
compared to only six patients in the non-MTOC cohort (23%
versus 6%, respectively; p  0.0002 using a two-sided
Fisher’s exact test).
DISCUSSION
A multidisciplinary approach for the evaluation and
treatment of lung cancer patients has been widely advocated
and adopted at many academic and nonacademic centers.
Disease presentations are often complex, and many patients
benefit from multimodal therapies that include medical man-
agement, surgery, chemotherapy, radiation therapy, and pal-
liative care services. Multidisciplinary clinics have been rec-
ommended as a way to provide care for these patients. The
close proximity of patient providers within these clinics
ideally results in open communication, streamlined evalua-
tions, and consensus for treatment plans. Patient convenience
has been touted as an additional strength as well. Potential
drawbacks, however, include issues regarding provider com-
pensation, physician availability, patient time requirements,
and changes in referral patterns.
The benefits of a multidisciplinary clinic in the evalu-
ation and treatment of breast cancer patients, for example,
have previously been reported.5 Sequential cohorts of breast
cancer patients were examined in a single-center study. One
cohort was evaluated during the year before the opening of a
multidisciplinary clinic, with the second cohort evaluated
during its first year of operation. The presence of a multidis-
ciplinary breast cancer clinic resulted in a statistically signif-
icant improvement in patient satisfaction as well as an im-
proved time between diagnosis and treatment initiation (42.2
days versus 29.6 days; p  0.0008).
Despite widespread adoption of multidisciplinary clin-
ics for the evaluation and management of lung cancer pa-
tients, evidence to support these clinics is limited. This
retrospective analysis of sequential cohorts failed to reveal
significant benefit in overall TTD, TTT, SCTD, SCTS, or
overall survival (NSCLC diagnoses) for individuals during
the time period of MTOC operation or the subgroup seen in
the MTOC itself. Although referral time to MTOC was 3
days longer, compared to conventional subspecialty referral,
this was offset by a shorter SCTD.
While power calculations may be considered less valid
in a retrospective study due to a fixed sample size, we believe
that the power calculations in our study may help to better
understand and interpret the negative findings. In particular,
the large “minimally detectable” effect size (34% reduction in
TTD, for example) suggests that a smaller but still clinically
meaningful advantage for the MTOC may still exist, but a
larger study would be required to detect such a difference.
Although not an originally planned outcome measure,
clinical trial enrollment did reveal a statistically significant
difference favoring the presence of the MTOC in our study. We
fully recognize the limitations, numerous confounders, and bi-
ases associated with such an analysis and recommend a prospec-
tive evaluation before drawing any further conclusions.
Interestingly, the lack of surgical involvement in the
formal clinic did not appear to delay time to surgery for the
MTOC cohort. In fact, time to surgery for both cohorts was
comparable to previously published data. Billing and Wells6
FIGURE 4. Overall survival for non-small cell lung cancer
diagnoses by patient cohort using intention to treat (top)
and treatment received (bottom) analyses. Survival was cal-
culated by the Kaplan-Meier method. Subjects are shown as
censored by open (non-MTOC) and closed (MTOC) circles
at the time of last follow-up. MTOC, operational multidisci-
plinary thoracic oncology clinic; Non-MTOC, nonoperational
multidisciplinary thoracic oncology clinic; CI  confidence
interval.
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performed a retrospective analysis of patients referred to a
single surgical unit in the United Kingdom. The mean time
from presentation to operation was 109 days, which is at least
comparable to our results (referral time  SCTS). Fergusson et
al.,7 in a study of 620 patients, found that 87% of patients were
diagnosed within 14 days of referral to a multidisciplinary group
of clinicians, similar to the 12 days found in our study.
The applicability of these results may be limited as a
result of the male-only population within a Veterans Affairs
hospital setting. The Durham VA Medical Center is a 274-
bed tertiary care referral, teaching, and research facility
affiliated with the Duke University School of Medicine.
Nonteaching affiliated hospitals, community-based hospital
facilities, and non-health maintenance organization practices
may not be able to apply these results to their organizational
practice patterns.
Although the cohorts had largely similar patient char-
acteristics, the retrospective nature of this study raises the
potential for unforeseen biases resulting in differences be-
tween groups that were not readily apparent. Socioeconomic
factors, such as education and/or income, as well as travel
distance to MTOC, may have resulted in unmeasured imbal-
ances between cohorts.
Importantly, the non-MTOC cohort was analyzed dur-
ing a period after the MTOC had existed, rather than before.
The presence of an electronic medical record, allowing for
rapid data collection and confirmation, was a main driving
force for this study design. Consequently, existing infrastruc-
tures, instituted during the operation of MTOC, may have
resulted in improvements in efficiency for both the diagnosis
and treatment of patients in the non-MTOC cohort. Similarly,
learned experiences by participating MTOC providers may
have carried through into the time period when MTOC did
not exist, masking any benefit attributable to MTOC.
Most importantly, despite the discontinuation of
MTOC in June 2002, the weekly multidisciplinary confer-
ence continues to this day. Thus, the MTOC conference may
negate or compensate for differences that may have existed
between groups as there is still a mechanism in place whereby
patients can be discussed in an open-forum between multiple
subspecialists. It is also possible that differences exist favor-
ing the presence of a multidisciplinary clinic that were not
identified by this study.
There may also be other benefits to a multidisciplinary
clinic that were not measured, such as patient satisfaction.
Murray et al.8 performed a randomized pilot study comparing
conventional methods of investigation in local clinics to a
centralized two-stop pathway. Eighty-eight patients were en-
rolled with 45 and 43 patients in the central and conventional
arms, respectively. Time to first treatment was improved by 4
weeks in the central arm (p  0.0025). Patients in the
conventional arm also thought the diagnostic process to be
too slow (p  0.02), whereas patients in the central arm had
better care experiences (p  0.01) and fewer visits to a
general practitioner (p  0.01).
Comparing the utilization of resources, quality-of-life
measures, and the quality of care provided may have identi-
fied differences as well. Examination of surgical resection
rates in our study, as a surrogate of quality care, revealed that
70% of patients with stage I-II NSCLC underwent surgical
resection during the period of MTOC operation compared to
71% of patients when the MTOC did not exist. The remaining
30% of patients in each group refused surgery or had func-
tional limitations that precluded surgical intervention. When
the analysis is limited to patients who had actually experi-
enced MTOC as an intervention, resection rates for stage I-II
NSCLC was 74% in the MTOC cohort.
As evidenced by this study, the presence of a formal
multidisciplinary clinic did not affect the timeliness of care.
This conclusion needs to be validated in other health care
settings, preferably in a prospective fashion. The continued
efforts of a weekly multidisciplinary conference, in the ab-
sence of a clinic, have not resulted in a measurable detriment
to patient care, based on the outcomes assessed. The contin-
uation of MTOC-based infrastructures, past provider experi-
ences, and other potential biases may have masked true
differences between groups. Analysis of a patient cohort
before the MTOC existence is warranted.
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